Cytokinetics (CYTK) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cytokinetics (CYTK) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cytokinetics's market cap?
Cytokinetics (CYTK) has a market capitalization of approximately
How profitable is Cytokinetics?
Cytokinetics runs a net profit margin of -784.0%, a gross margin of 90.3%, and an operating margin of -605.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cytokinetics generate?
Cytokinetics reported revenue of $88M for fiscal year 2025, with net income of -$785M and earnings per share (EPS) of -6.54. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Cytokinetics pay a dividend?
Cytokinetics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Cytokinetics financially healthy?
Cytokinetics carries a debt-to-equity ratio of -1.56x and a current ratio of 4.21x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cytokinetics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cytokinetics (CYTK) the key facts are: market cap
Track Cytokinetics's full fundamentals live
Get Cytokinetics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.